MedTrace Logo

The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma

NCT03652467 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-02-22

No results posted yet for this study

Summary

To investigate the safety and efficacy of deferoxamine (DFO) combined with conventional transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma (HCC).

Conditions

  • Hepatocellular Carcinoma Non-resectable

Interventions

DRUG

Conventional TACE

Conventional chemoembolization drugs are injected through hepatic artery.

DRUG

Deferoxamine and conventional TACE

Deferoxamine is injected before conventional transarterial chemoembolization.

Sponsors & Collaborators

  • Jinan Military General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2022-09-01
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03652467 on ClinicalTrials.gov